Armen Shanafelt - Net Worth and Insider Trading
Armen Shanafelt Net Worth
The estimated net worth of Armen Shanafelt is at least $100 Million dollars as of 2024-09-20. Armen Shanafelt is the Director, 10% Owner of Protagonist Therapeutics Inc and owns about 2,099,482 shares of Protagonist Therapeutics Inc (PTGX) stock worth over $96 Million. Armen Shanafelt is the Director, 10% Owner of Surface Oncology Inc and owns about 3,447,817 shares of Surface Oncology Inc (SURF) stock worth over $4 Million. Armen Shanafelt is also the Director of Spyre Therapeutics Inc and owns about 6,000 shares of Spyre Therapeutics Inc (SYRE) stock worth over $182,340. Besides these, Armen Shanafelt also holds Aileron Therapeutics Inc (ALRN) . Details can be seen in Armen Shanafelt's Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Armen Shanafelt has not made any transactions after 2021-12-13 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.
Transaction Summary of Armen Shanafelt
Armen Shanafelt Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Armen Shanafelt owns 4 companies in total, including Surface Oncology Inc (SURF) , Spyre Therapeutics Inc (SYRE) , and Aileron Therapeutics Inc (ALRN) among others .
Click here to see the complete history of Armen Shanafelt’s form 4 insider trades.
Insider Ownership Summary of Armen Shanafelt
| Ticker | Comapny | Transaction Date | Type of Owner |
|---|---|---|---|
| SURF | Surface Oncology Inc | 2018-04-23 | director & 10 percent owner |
| SYRE | Spyre Therapeutics Inc | 2021-12-13 | 10 percent owner |
| ALRN | Aileron Therapeutics Inc | 2017-07-05 | director & 10 percent owner |
 | | 2016-08-16 | director & 10 percent owner |
Armen Shanafelt Latest Holdings Summary
Armen Shanafelt currently owns a total of 4 stocks. Among these stocks, Armen Shanafelt owns 2,099,482 shares of Protagonist Therapeutics Inc (PTGX) as of August 16, 2016, with a value of $96 Million and a weighting of 95.99%. Armen Shanafelt owns 3,447,817 shares of Surface Oncology Inc (SURF) as of April 23, 2018, with a value of $4 Million and a weighting of 3.67%. Armen Shanafelt also owns 6,000 shares of Spyre Therapeutics Inc (SYRE) as of December 13, 2021, with a value of $182,340 and a weighting of 0.18%. The other 1 stocks Aileron Therapeutics Inc (ALRN) have a combined weighting of 0.16% among all his current holdings.
Latest Holdings of Armen Shanafelt
| Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
|---|---|---|---|---|---|
| PTGX | Protagonist Therapeutics Inc | 2016-08-16 | 2,099,482 | 45.92 | 96,408,213 |
| SURF | Surface Oncology Inc | 2018-04-23 | 3,447,817 | 1.07 | 3,689,164 |
| SYRE | Spyre Therapeutics Inc | 2021-12-13 | 6,000 | 30.39 | 182,340 |
| ALRN | Aileron Therapeutics Inc | 2017-07-05 | 54,749 | 2.91 | 159,320 |
Holding Weightings of Armen Shanafelt
Armen Shanafelt Form 4 Trading Tracker
According to the SEC Form 4 filings, Armen Shanafelt has made a total of 0 transactions in Protagonist Therapeutics Inc (PTGX) over the past 5 years. The most-recent trade in Protagonist Therapeutics Inc is the acquisition of 583,333 shares on August 16, 2016, which cost Armen Shanafelt around $7 Million.
According to the SEC Form 4 filings, Armen Shanafelt has made a total of 0 transactions in Surface Oncology Inc (SURF) over the past 5 years. The most-recent trade in Surface Oncology Inc is the acquisition of 266,000 shares on April 23, 2018, which cost Armen Shanafelt around $4 Million.
According to the SEC Form 4 filings, Armen Shanafelt has made a total of 1 transactions in Spyre Therapeutics Inc (SYRE) over the past 5 years, including 1 buys and 0 sells. The most-recent trade in Spyre Therapeutics Inc is the acquisition of 6,000 shares on December 13, 2021, which cost Armen Shanafelt around $549,000.
More details on Armen Shanafelt's insider transactions can be found in the Insider Trading History of Armen Shanafelt table.Insider Trading History of Armen Shanafelt
- 1
Armen Shanafelt Trading Performance
GuruFocus tracks the stock performance after each of Armen Shanafelt's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Armen Shanafelt is 21.73%. GuruFocus also compares Armen Shanafelt's trading performance to market benchmark return within the same time period. The performance of stocks bought by Armen Shanafelt within 3 months outperforms 3 times out of 4 transactions in total compared to the return of S&P 500 within the same period.
You can select different timeframes to see how Armen Shanafelt's insider trading performs compared to the benchmark.
Performance of Armen Shanafelt
Average Return
Outperforming Transactions
| 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | 3 Years | |
|---|---|---|---|---|---|---|
| Return(%) | 13.8 | | | | | |
| Relative Return to S&P 500(%) | 13.25 | | | | | |
Armen Shanafelt Ownership Network
Armen Shanafelt Owned Company Details
What does Surface Oncology Inc do?
Who are the key executives at Surface Oncology Inc?
Armen Shanafelt is the director & 10 percent owner of Surface Oncology Inc. Other key executives at Surface Oncology Inc include Deputy GC Chandra Adams , Chief Medical Officer Alison Oneill , and See Remarks Jessica Fees .
Surface Oncology Inc (SURF) Insider Trades Summary
Over the past 18 months, Armen Shanafelt made no insider transaction in Surface Oncology Inc (SURF). Other recent insider transactions involving Surface Oncology Inc (SURF) include a net sale of 16,713 shares made by Robert W. Ross , a net sale of 9,434 shares made by Jessica Fees , and a net sale of 7,042 shares made by Alison Oneill .
In summary, during the past 3 months, insiders sold 0 shares of Surface Oncology Inc (SURF) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 37,090 shares of Surface Oncology Inc (SURF) were sold and 0 shares were bought by its insiders, resulting in a net sale of 37,090 shares.
Surface Oncology Inc (SURF)'s detailed insider trading history can be found in Insider Trading Tracker table.
Surface Oncology Inc Insider Transactions
Armen Shanafelt Mailing Address
Above is the net worth, insider trading, and ownership report for Armen Shanafelt. You might contact Armen Shanafelt via mailing address: C/o Lilly Ventures Fund I, Llc, 115 W. Washington Street,ste 1680-south, Indianapolis In 46204.
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
